gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 11 Dec 2014.

Apolipoprotein B

apolipoprotein B, apoB, Apolipoprotein B-100, apoB-100
This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: HDL, HAD, AGE, CAN, ACID
Papers using apolipoprotein B antibodies
siRNA off-target effects can be reduced at concentrations that match their individual potency
Harada-Shiba Mariko et al., In Molecular Therapy. Nucleic Acids, 2010
... Membranes were then incubated with primary antibody for mouse apoB-100 or -48 (Meridian Life Science, Inc., Saco, ME) for ...
Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins
Reitsma Pieter H., In PLoS ONE, 2008
... the goat polyclonal IgG to human apolipoprotein A-II and the goat polyclonal IgG to human apolipoprotein B were from Abcam (Cambridge, UK) ...
Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice.
Polidori Carlo, In PLoS ONE, 2001
... Seven-week-old male C57Bl/6 and human apoB-transgenic mice (B6.SJL-Tg(APOB)1102Sgy-mice backcrossed to ...
A third-generation lentivirus vector with a conditional packaging system.
Lindenbach Brett D., In PLoS Pathogens, 1997
... Antibodies were obtained from the following companies: Apolipoprotein B (Millipore); PLA2G4A (Abcam ...
more suppliers
Papers on apolipoprotein B
Progress on ovine lentivirus and its resistant genes.
Wang et al., Hangzhou, China. In Yi Chuan, 20 Jan 2015
Here, we review the progress of E35K mutation in sheep TMEM154 gene and its effects on resistance to MVV, and other lentivirusresistant genes including zinc finger cluster, chemokine reveptor 5 (CCR5), tripartite motif-containing 5 alpha (TRIM5Α), apolipoprotein B mRNA-editing catalytic polypetide like 3 (APOBEC3), developmental pluripotencyassociated 2 (DPPA2) and DPPA4.
Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.
Elisaf et al., Ioánnina, Greece. In Expert Opin Biol Ther, 10 Jan 2015
Expert opinion: These new agents are administered subcutaneously and have been shown to have major LDL-C and apoB lowering effects either alone or in combination with statins.
GCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment.
Anthony et al., United States. In Am J Physiol Endocrinol Metab, 09 Jan 2015
Furthermore, rates of triglyceride export and protein expression of ApoB 100 were significantly reduced in the livers of Gcn2 null mice treated with asparaginase, providing a mechanistic basis for the increase in hepatic lipid content.
HIV-1 viral infectivity factor interacts with light chain 3 and inhibits autophagy.
Biard-Piechaczyk et al., Strasbourg, France. In Aids, 08 Jan 2015
Pull-down experiments, immunoprecipitation assays and computational analyses were performed to analyze the interaction between Vif and light chain 3B (LC3B), a major autophagy component, in presence or absence of the antiviral host factor apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G), after HIV-1 infection or ectopic expression of Vif.
Use of Lipoprotein Particle Measures for Assessing Coronary Heart Disease Risk Post-American Heart Association/American College of Cardiology Guidelines: The Multi-Ethnic Study of Atherosclerosis.
Tsai et al., Bethesda, United States. In Arterioscler Thromb Vasc Biol, 04 Jan 2015
OBJECTIVE: The American College of Cardiology and American Heart Association have issued guidelines indicating that the contribution of apolipoprotein B-100 (ApoB) to cardiovascular risk assessment remains uncertain.
Hypermutation in human cancer genomes: footprints and mechanisms.
Gordenin et al., Durham, United States. In Nat Rev Cancer, 24 Dec 2014
This major expansion of cancer mutation data sets has provided unprecedented statistical power for the analysis of mutation spectra, which has confirmed several classical sources of mutation in cancer, highlighted new prominent mutation sources (such as apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC) enzymes) and empowered the search for cancer drivers.
LOX-1 in atherosclerotic disease.
Okamura et al., Matsumoto, Japan. In Clin Chim Acta, 22 Dec 2014
We hypothesized that LOX-1 is a candidate risk factor beyond LDL cholesterol (LDLC) and developed a novel assay to quantify LOX-1 ligand containing apoB (LAB).
ETC-1002: A future option for lipid disorders?
Banach et al., Palermo, Italy. In Atherosclerosis, 01 Dec 2014
The levels of apolipoprotein B (apoB) and non-high density lipoprotein cholesterol (non-HDL-C) were also reduced with beneficial effect on other cardiometabolic factors such as inflammatory markers, blood pressure and body weight.
Peripheral arterial disease, type 2 diabetes and postprandial lipidaemia: Is there a link?
Pérez-López et al., Málaga, Spain. In World J Diabetes, 15 Nov 2014
Additionally, the use of certain specific postprandial particle markers, such as apolipoprotein B-48, makes it easier and more simple to approach the postprandial phenomenon.
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
Kastelein et al., Amsterdam, Netherlands. In J Am Coll Cardiol, Sep 2014
OBJECTIVES: The aim of this meta-analysis was to evaluate: 1) the interindividual variability of reductions in low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), or apolipoprotein B (apoB) levels achieved with statin therapy; 2) the proportion of patients not reaching guideline-recommended lipid levels on high-dose statin therapy; and 3) the association between very low levels of atherogenic lipoproteins achieved with statin therapy and cardiovascular disease risk.
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
DESCARTES Investigators et al., Stellenbosch, South Africa. In N Engl J Med, Jun 2014
Evolocumab treatment also significantly reduced levels of apolipoprotein B, non-high-density lipoprotein cholesterol, lipoprotein(a), and triglycerides.
The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is reversed by Wnt3a rescue.
Mani et al., New Haven, United States. In Cell Metab, Mar 2014
Further investigation showed that LRP6(R611C) mutation triggers hepatic de novo lipogenesis, lipid and cholesterol biosynthesis, and apoB secretion by an Sp1-dependent activation of IGF1, AKT, and both mTORC1 and mTORC2.
[The clinical biochemistry of hypo-lipedemic therapy and mechanisms of action of statins: the fatty acids, statins and diabetes mellitus].
Titov, In Klin Lab Diagn, Feb 2014
The statins, decreasing content of non-esterified cholesterol in monolayer, activate hydrolysis of triglycerides in lipoproteins of very low density, formation of lipoproteins of low density and their absorption by cells through apoB-100 receptors.
MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion.
Hussain et al., New York City, United States. In Nat Med, Jul 2013
We show that microRNA-30c (miR-30c) interacts with the 3' untranslated region of MTP mRNA and induces its degradation, leading to reductions in MTP activity and in apolipoprotein B (APOB) secretion.
IRE1α-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis.
Kaufman et al., Los Angeles, United States. In Cell Metab, 2012
Hepatocyte-specific deletion of Ire1α reduces lipid partitioning into the ER lumen and impairs the assembly of triglyceride (TG)-rich VLDL but does not affect TG synthesis, de novo lipogenesis, or the synthesis or secretion of apolipoprotein B (apoB).
Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism.
Rader et al., Philadelphia, United States. In J Clin Invest, 2012
model in which increased hepatic sortilin binds intracellular APOB-containing particles in the Golgi apparatus as well as extracellular LDL at the plasma membrane and traffics them to the lysosome for degradation
Elevated ApoB serum levels strongly predict early cardiovascular events.
de Faire et al., Stockholm, Sweden. In Heart, 2012
Data indicate that increased ApoB serum levels are important predictors of early cardiovascular events.
ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1.
Yaniv et al., Israel. In Nat Med, 2012
found that ApoB negatively regulates angiogenesis and that it is the ApoB protein particle
A prospective genetic marker of the visual-perception disorder Meares-Irlen syndrome.
Watson et al., Armidale, Australia. In Percept Mot Skills, 2012
APOB 3' VNTR locus is a potential marker for susceptibility to Meares-Irlen syndrome and perhaps other related conditions
Synthesis, conformation and vibrational dynamics of the peptide -Ser-Cys-Lys-Leu-Asp-Phe-, a fragment of apolipoprotein B.
Vijai Prakash et al., Lucknow, India. In Indian J Biochem Biophys, 2002
Synthesis, conformation and vibrational dynamics of the peptide -Ser-Cys-Lys-Leu-Asp-Phe-, a fragment of apolipoprotein B
More papers using apolipoprotein B antibodies
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo.
Lindenbach Brett, In PLoS ONE, 1996
... Heart Institute (University of Ottawa, Ontario, Canada), anti-apoB (clone 1609) monoclonal antibodies and peroxidase-conjugated goat anti-apoB antibodies were from Biodesign (Saco, ME, USA) ...
PKC gamma mutant mice exhibit mild deficits in spatial and contextual learning
Skoulakis Efthimios M. C., In PLoS ONE, 1992
... ApoB-100 transgenic mice were produced in ...
share on facebooktweetadd +1mail to friends